Liver cancer is a frequent disease. Patients with liver cancer have most of the time an underlying chronic liver disease, often without knowing it since the liver is an organ which does not trigger pain. However, it is possible to cure patients from their liver cancer when the diagnosis is done at an early stage. Therefore diagnostic tools for detecting liver cancer are of utmost importance.
Therapeutically great progresses have been realized in the last years, patients have access to more possible treatments. But the treatment of patients with liver cancer is complex.
The Swiss Foundation against Liver Cancer aims at disseminating information about this disease to increase awareness and to support research to improve the diagnosis, therapy and management of patients and families confronted with this disease.
In a recent “Ask the Author” session, Professor Kudo discussed the LEAP-012 trial and its implications for treating hepatocellular carcinoma (HCC) with Professor Dufour. The study, titled “TACE combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic HCC LEAP-012,” investigates a novel approach to treating this condition. Watch the Full Interview here Background
In the ever-evolving landscape of hepatocellular carcinoma (HCC) treatment, every breakthrough brings us closer to improving patient outcomes. We are thrilled to present an exclusive interview with Professor Andrea Casadei-Gardini, a leading expert in oncology, who shares pivotal findings from his recent paper, “Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to
In our recent podcast lead by Prod. Jean-François Dufour, we had the privilege of speaking with Professor Michel Ducreux, a leading expert in the field of oncology from Paris, France. The discussion focused on the evolving landscape of liver cancer treatment and the latest advancements that are reshaping patient care. Below you will find the
